Home
/
Century Therapeutics, Inc. (IPSC)
Century Therapeutics, Inc. (IPSC) Technical Analysis
Updated: 2026-05-01 03:14 UTC · Last close: 2.29 (+4.09%) · Support: 2.21 · Resistance: 2.46
Century Therapeutics, Inc. (IPSC) technical analysis page covering price structure, support and resistance, momentum conditions and a fundamentals snapshot from WOI Scanner.
⚠️ Risk Line
losing 2.21 would weaken the current structure.
Quick Read
The nearest decision zone is framed by support around 2.21 and resistance near 2.46.
🎯 Decision Map
The nearest decision zone is framed by support around 2.21 and resistance near 2.46. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
📊 Technical Summary
The latest close for Century Therapeutics, Inc. (IPSC) came in at 2.29 (+4.09%). The chart is sitting below its 50-day average while still holding above the 200-day average, suggesting shorter-term weakness inside a still positive long-term backdrop. 20-day momentum is positive at +4.57%, with price remains inside its roughly 52-week range (0.47–2.94), while ATR14 volatility is elevated at roughly 7.03% of price. RSI(14) is 50.0, leaving momentum in a fairly neutral range. RSI has been trending higher in recent sessions, indicating improving momentum conditions. MACD remains below its signal line, which shows that momentum confirmation is still limited. The MACD histogram remains negative, suggesting momentum is still on the softer side. Recent trading volume is running below its typical 20-day average, which suggests participation remains relatively muted. Near-term structure is defined by support at 2.21 and resistance at 2.46. A clean break above resistance would strengthen the chart, while a loss of support would put the current setup under pressure. Fundamentals snapshot: Revenue: 109.16M · Net income: -34.42M · EPS (basic): -0.40. The interactive chart adds overlays, pattern context and a fuller structure view for deeper review.
💼 Fundamentals Snapshot
Source: sec
Company
Century Therapeutics, Inc.
Note: This is an algorithmic technical snapshot (not financial advice).